GenMont Biotech Inc - Asset Resilience Ratio
GenMont Biotech Inc (3164) has an Asset Resilience Ratio of 19.50% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read GenMont Biotech Inc (3164) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how GenMont Biotech Inc's Asset Resilience Ratio has changed over time. See 3164 total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down GenMont Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of GenMont Biotech Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$307.92 Million | 19.5% |
| Total Liquid Assets | NT$307.92 Million | 19.50% |
Asset Resilience Insights
- Good Liquidity Position: GenMont Biotech Inc maintains a healthy 19.50% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
GenMont Biotech Inc Industry Peers by Asset Resilience Ratio
Compare GenMont Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for GenMont Biotech Inc (2003–2024)
The table below shows the annual Asset Resilience Ratio data for GenMont Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.52% | NT$248.13 Million ≈ $7.82 Million |
NT$1.71 Billion ≈ $53.83 Million |
-1.97pp |
| 2023-12-31 | 16.50% | NT$272.71 Million ≈ $8.59 Million |
NT$1.65 Billion ≈ $52.08 Million |
+0.74pp |
| 2022-12-31 | 15.76% | NT$267.26 Million ≈ $8.42 Million |
NT$1.70 Billion ≈ $53.43 Million |
+0.93pp |
| 2021-12-31 | 14.83% | NT$251.78 Million ≈ $7.93 Million |
NT$1.70 Billion ≈ $53.50 Million |
+3.03pp |
| 2020-12-31 | 11.80% | NT$190.28 Million ≈ $5.99 Million |
NT$1.61 Billion ≈ $50.81 Million |
-9.51pp |
| 2019-12-31 | 21.31% | NT$334.80 Million ≈ $10.55 Million |
NT$1.57 Billion ≈ $49.50 Million |
-21.00pp |
| 2018-12-31 | 42.31% | NT$701.60 Million ≈ $22.10 Million |
NT$1.66 Billion ≈ $52.25 Million |
+28.86pp |
| 2017-12-31 | 13.44% | NT$201.69 Million ≈ $6.35 Million |
NT$1.50 Billion ≈ $47.26 Million |
+4.45pp |
| 2016-12-31 | 8.99% | NT$126.24 Million ≈ $3.98 Million |
NT$1.40 Billion ≈ $44.23 Million |
-2.69pp |
| 2015-12-31 | 11.68% | NT$190.89 Million ≈ $6.01 Million |
NT$1.63 Billion ≈ $51.47 Million |
+12.49pp |
| 2014-12-31 | -0.81% | NT$-14.05 Million ≈ $-442.56K |
NT$1.74 Billion ≈ $54.88 Million |
-44.92pp |
| 2013-12-31 | 44.11% | NT$606.01 Million ≈ $19.09 Million |
NT$1.37 Billion ≈ $43.28 Million |
-4.03pp |
| 2012-12-31 | 48.15% | NT$687.66 Million ≈ $21.66 Million |
NT$1.43 Billion ≈ $45.00 Million |
-11.31pp |
| 2011-12-31 | 59.46% | NT$887.58 Million ≈ $27.96 Million |
NT$1.49 Billion ≈ $47.03 Million |
+71.86pp |
| 2010-12-31 | -12.40% | NT$-169.36 Million ≈ $-5.34 Million |
NT$1.37 Billion ≈ $43.02 Million |
-61.81pp |
| 2007-12-31 | 49.41% | NT$282.47 Million ≈ $8.90 Million |
NT$571.68 Million ≈ $18.01 Million |
+48.57pp |
| 2006-12-31 | 0.84% | NT$4.39 Million ≈ $138.18K |
NT$520.93 Million ≈ $16.41 Million |
-0.48pp |
| 2005-12-31 | 1.32% | NT$4.15 Million ≈ $130.87K |
NT$313.55 Million ≈ $9.88 Million |
-25.08pp |
| 2004-12-31 | 26.41% | NT$81.62 Million ≈ $2.57 Million |
NT$309.07 Million ≈ $9.74 Million |
-0.65pp |
| 2003-12-31 | 27.06% | NT$69.88 Million ≈ $2.20 Million |
NT$258.26 Million ≈ $8.14 Million |
-- |
About GenMont Biotech Inc
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan. It offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products. The company was founded in 2000 and is based in Tainan City, Taiwan.